+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cystic Fibrosis Drug Market, Share & Trends Analysis Report by Drug Type, by Drug Administration (Oral, Injection), by Application (Hospitals, Clinics, Others), by Region, Competitive Strategies and Segment Forecasts, 2016- 2026

  • ID: 5351583
  • Report
  • August 2019
  • Region: Global
  • 122 pages
  • Reports and Data
Increasing prevalence of cystic fibrosis, and rising need for treatments to reduce burden of disease are key factors driving market revenue growth.

Market Size - USD 6.49 Billion in 2020, Market Growth - CAGR of 16.8%, Market Trends - Rising investments by major players in research and development of advanced and novel drugs.

The global cystic fibrosis drug market size is expected to reach USD 22.41 Billion in 2028, and register a CAGR of 16.8% during the forecast period. Rising awareness regarding identified mutations and need for constant research and development of treatment and drugs is a major factor constantly driving growth of the global cystic fibrosis drug market. At present, there are around 1900 identified CFTR mutations that are responsible for cystic fibrosis diseases and treatments have been found for only about half of the mutations.

Cystic fibrosis, also known as mucoviscidosis, is a genetic disorder, which generally affects the lungs, but also the pancreas, liver, kidneys, and intestine.

However, high cost of cystic fibrosis drugs is a major factor that could hamper its adoption rate and restrain growth of the global cystic fibrosis drug market.

Some Key Findings From the Report:
  • Among the drug administration segments, the oral segment accounted for the largest revenue share of 71.4% in 2020.
  • North America cystic fibrosis drug market is expected to dominate in the global market over the forecast period, due to increasing spending on personal health and wellness, well-developed healthcare sector, various initiatives and projects undertaken by non-profit organizations, and strong presence of several major players including Vertex Pharmaceuticals.
  • The Asia Pacific market was valued at USD 1.80 Billion in 2020, and is expected to register the highest revenue growth rate during the forecast period.
  • Key players profiled in the report include Vertex Pharmaceuticals, F.Hoffmann-La Roche, AbbVie, Gilead Sciences, Novartis, Allergan, Chiesi Farmaceutici S.p.A., Actavis, Arcturus Therapeutics, Boehringer Ingelheim, Genzyme, Insmed, Pharmaxis, Proteostasis Therapeutics, and Venus Remedies. The market players have adopted various strategies including mergers, acquisitions, partnerships, and new product developments, among other strategies, to stay ahead of the competition and expand market footprint.
For the purpose of this report, the global cystic fibrosis drug market is segmented on the basis of drug type, drug administration, application, and region:

Drug Type Outlook
  • Pancreatic Enzyme Supplements
  • Multivitamins
  • Mucolytics
  • Antibiotics
  • Bronchodilators
  • Anti-Inflammatory Agents
  • CFTR Potentiators
  • Others
Drug Administration Outlook
  • Oral
  • Injection
Application Outlook
  • Hospitals
  • Clinics
  • Others
Region Outlook
  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Benelux
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Rest of Latin America
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa
Reasons to Buy the Report
  • A robust analysis and estimation of the Cystic Fibrosis Drug Market with four levels of quality check - in-house database, expert interviews, governmental regulation, and a forecast specifically done through time series analysis
  • A holistic competitive landscape of the all the major players in the Cystic Fibrosis Drug Market. The report covers their market shares, strategic initiatives, new product launches, R&D expenditure, M&As, Joint ventures, expansionary plans, product wise metric space analysis and key developments
  • Go-to-market strategies specifically formulated in line with location analysis which takes into the factors such as government regulations, supplier mapping, supply chain obstacles, and feedback from local vendors
  • Most deep dive segmental bifurcation available currently in the market. Our stellar methodology helps us understand the overall gamut of the supply chain and will help you explain the current market dynamics
  • Special focus given on vendor landscape, supplier portfolio, customer mapping, production capacity, and yearly capacity utilization
Note: Product cover images may vary from those shown
1 Cystic Fibrosis Drugs Market Overview
1.1 Product Overview and Scope of Cystic Fibrosis Drugs
1.2 Cystic Fibrosis Drugs Segment by Type (Product Category)
1.2.1 Global Cystic Fibrosis Drugs Production and CAGR (%) Comparison by Type (Product Category)(2012-2022)
1.2.2 Global Cystic Fibrosis Drugs Production Market Share by Type (Product Category) in 2016
1.2.3 Oral
1.2.4 Injection
1.3 Global Cystic Fibrosis Drugs Segment by Application
1.3.1 Cystic Fibrosis Drugs Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Cystic Fibrosis Drugs Market by Region (2012-2022)
1.4.1 Global Cystic Fibrosis Drugs Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Cystic Fibrosis Drugs (2012-2022)
1.5.1 Global Cystic Fibrosis Drugs Revenue Status and Outlook (2012-2022)
1.5.2 Global Cystic Fibrosis Drugs Capacity, Production Status and Outlook (2012-2022)

2 Global Cystic Fibrosis Drugs Market Competition by Manufacturers
2.1 Global Cystic Fibrosis Drugs Capacity, Production and Share by Manufacturers (2012-2017)
2.1.1 Global Cystic Fibrosis Drugs Capacity and Share by Manufacturers (2012-2017)
2.1.2 Global Cystic Fibrosis Drugs Production and Share by Manufacturers (2012-2017)
2.2 Global Cystic Fibrosis Drugs Revenue and Share by Manufacturers (2012-2017)
2.3 Global Cystic Fibrosis Drugs Average Price by Manufacturers (2012-2017)
2.4 Manufacturers Cystic Fibrosis Drugs Manufacturing Base Distribution, Sales Area and Product Type
2.5 Cystic Fibrosis Drugs Market Competitive Situation and Trends
2.5.1 Cystic Fibrosis Drugs Market Concentration Rate
2.5.2 Cystic Fibrosis Drugs Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Cystic Fibrosis Drugs Capacity, Production, Revenue (Value) by Region (2012-2017)
3.1 Global Cystic Fibrosis Drugs Capacity and Market Share by Region (2012-2017)
3.2 Global Cystic Fibrosis Drugs Production and Market Share by Region (2012-2017)
3.3 Global Cystic Fibrosis Drugs Revenue (Value) and Market Share by Region (2012-2017)
3.4 Global Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.5 North America Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.6 Europe Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.7 China Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.8 Japan Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.9 Southeast Asia Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.10 India Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Cystic Fibrosis Drugs Supply (Production), Consumption, Export, Import by Region (2012-2017)
4.1 Global Cystic Fibrosis Drugs Consumption by Region (2012-2017)
4.2 North America Cystic Fibrosis Drugs Production, Consumption, Export, Import (2012-2017)
4.3 Europe Cystic Fibrosis Drugs Production, Consumption, Export, Import (2012-2017)
4.4 China Cystic Fibrosis Drugs Production, Consumption, Export, Import (2012-2017)
4.5 Japan Cystic Fibrosis Drugs Production, Consumption, Export, Import (2012-2017)
4.6 Southeast Asia Cystic Fibrosis Drugs Production, Consumption, Export, Import (2012-2017)
4.7 India Cystic Fibrosis Drugs Production, Consumption, Export, Import (2012-2017)

5 Global Cystic Fibrosis Drugs Production, Revenue (Value), Price Trend by Type
5.1 Global Cystic Fibrosis Drugs Production and Market Share by Type (2012-2017)
5.2 Global Cystic Fibrosis Drugs Revenue and Market Share by Type (2012-2017)
5.3 Global Cystic Fibrosis Drugs Price by Type (2012-2017)
5.4 Global Cystic Fibrosis Drugs Production Growth by Type (2012-2017)

6 Global Cystic Fibrosis Drugs Market Analysis by Application
6.1 Global Cystic Fibrosis Drugs Consumption and Market Share by Application (2012-2017)
6.2 Global Cystic Fibrosis Drugs Consumption Growth Rate by Application (2012-2017)
6.3 Market Drivers and Opportunities
6.3.1 Potential Applications
6.3.2 Emerging Markets/Countries

7 Global Cystic Fibrosis Drugs Manufacturers Profiles/Analysis
7.1 Actavis
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Actavis Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 F. Hoffmann-La Roche
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 F. Hoffmann-La Roche Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 Gilead Sciences
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Gilead Sciences Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview
7.4 Novartis
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 Novartis Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.4.4 Main Business/Business Overview
7.5 Vertex Pharmaceuticals
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 Vertex Pharmaceuticals Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.5.4 Main Business/Business Overview
7.6 Abbott
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 Abbott Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.6.4 Main Business/Business Overview
7.7 Anthera Pharmaceuticals
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 Anthera Pharmaceuticals Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.7.4 Main Business/Business Overview
7.8 Arcturus Therapeutics
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 Arcturus Therapeutics Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.8.4 Main Business/Business Overview
7.9 Boehringer Ingelheim
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 Boehringer Ingelheim Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.9.4 Main Business/Business Overview
7.10 Chiesi Farmaceutici
7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.10.2 Cystic Fibrosis Drugs Product Category, Application and Specification
7.10.2.1 Product A
7.10.2.2 Product B
7.10.3 Chiesi Farmaceutici Cystic Fibrosis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.10.4 Main Business/Business Overview
7.11 Corbus Pharmaceuticals
7.12 Genzyme
7.13 Insmed
7.14 Johnson & Johnson
7.15 Merck Sharp & Dohme
7.16 Neovii Biotech
7.17 Novo Nordisk
7.18 PharmaSwiss
7.19 Pharmaxis
7.20 Proteostasis Therapeutics
7.21 PTC Therapeutics
7.22 United Medical
7.23 Venus Remedies

8 Cystic Fibrosis Drugs Manufacturing Cost Analysis
8.1 Cystic Fibrosis Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Cystic Fibrosis Drugs

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Cystic Fibrosis Drugs Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Cystic Fibrosis Drugs Major Manufacturers in 2015
9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

12 Global Cystic Fibrosis Drugs Market Forecast (2017-2022)
12.1 Global Cystic Fibrosis Drugs Capacity, Production, Revenue Forecast (2017-2022)
12.1.1 Global Cystic Fibrosis Drugs Capacity, Production and Growth Rate Forecast (2017-2022)
12.1.2 Global Cystic Fibrosis Drugs Revenue and Growth Rate Forecast (2017-2022)
12.1.3 Global Cystic Fibrosis Drugs Price and Trend Forecast (2017-2022)
12.2 Global Cystic Fibrosis Drugs Production, Consumption , Import and Export Forecast by Region (2017-2022)
12.2.1 North America Cystic Fibrosis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.2 Europe Cystic Fibrosis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.3 China Cystic Fibrosis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.4 Japan Cystic Fibrosis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.5 Southeast Asia Cystic Fibrosis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.6 India Cystic Fibrosis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.3 Global Cystic Fibrosis Drugs Production, Revenue and Price Forecast by Type (2017-2022)
12.4 Global Cystic Fibrosis Drugs Consumption Forecast by Application (2017-2022)

13 Research Findings and Conclusion

14 Appendix
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
Note: Product cover images may vary from those shown
Adroll
adroll